Drug: Pembrolizumab (Keytruda, Merck)
Status: Granted approval for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors with a microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) biomarker. This indication includes patients with solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options and patients with colorectal cancer that has progressed following treatment